| Patient | Flannery O'Connor |
|---|---|
| Date of birth | 2001-03-25 |
| Identifiers | MRN HR-ML046-SYN; SSN (made up) 000-46-1853 |
| Document date | 2026-07-27 |
| Author | Augusta Pemberton-Diallo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review of lupus nephritis. [S]
Ms. O'Connor is thirteen weeks into treatment. Her joint pain and swelling settled within three weeks and the facial rash has faded with sun protection; she has had no fevers. She takes prednisone 10 mg a day, reached a month ago, mycophenolate 1000 mg twice daily (loose stools in the first two weeks, since settled), weekly belimumab by her own injection, hydroxychloroquine, and losartan. The rheumatology blood counts, weekly for the first month and twice monthly since, have stayed normal, with white cells between 4.8 and 7.9 and normal liver tests. The bladder infection in June grew Escherichia coli sensitive to nitrofurantoin and cleared after seven days. Her baseline eye examination a month ago was normal. She has gained 3.4 kg and sleeps less well on the days after a dose reduction. She writes five mornings a week. [S]
| Element | Detail |
|---|---|
| Interval change | Arthritis, rash, and fevers resolved; cystitis in June resolved |
| Medicines | Prednisone 10 mg; mycophenolate 2 g a day; belimumab weekly; hydroxychloroquine; losartan |
| Monitoring | Blood counts and liver tests normal; eye examination normal |
| Work | Writing five mornings a week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Weight up 3.4 kg; no fever |
| Musculoskeletal | Negative | No joint pain; no hip, groin, or knee pain |
| Integumentary | Negative | Rash gone; hair shedding less |
| Gastrointestinal | Negative | Stools normal now |
| Genitourinary | Negative | No urinary symptoms |
| Psychiatric | Positive | Poor sleep on some nights; mood good; PHQ-9 4 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2026-04-13 | active | S |
| Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure | One tablet once daily | Oral route | 2026-04-22 | active | S |
| Methylprednisolone 500 mg intravenous infusion once daily for three days | One infusion daily for three days | Intravenous route | 2026-04-29 to 2026-05-01 | completed | S |
| Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months | Once daily, tapering | Oral route | 2026-04-29 | active | S |
| Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily | Two tablets twice daily | Oral route | 2026-04-29 | active | S |
| Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly | Once weekly by self-injection | Subcutaneous route | 2026-04-29 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-04-29 | active | S |
| Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven days | One capsule twice daily for seven days | Oral route | 2026-06-15 to 2026-06-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-27 | Body height | 168 | cm | S |
| 2026-07-27 | Body weight | 63.4 | kg | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-07-27 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-07-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-07-27 | Heart rate | 76 | /min | S |
| 2026-07-27 | Respiratory rate | 14 | /min | S |
| 2026-07-27 | Body temperature | 36.7 | Cel | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-27 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-07-27 | Leukocytes [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-07-27 | Lymphocytes [#/volume] in Blood by Automated count | 1 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 2026-07-27 | Platelets [#/volume] in Blood by Automated count | 212 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 2026-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-27 | Albumin [Mass/volume] in Serum or Plasma | 3.8 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-07-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | <=33 U/L | Normal | S |
| 2026-07-27 | Protein/Creatinine [Mass Ratio] in Urine | 0.9 | g/g | <=0.2 g/g | High | S |
| 2026-07-27 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 6 | /[HPF] | <=2 /[HPF] | High | S |
| 2026-07-27 | DNA double strand Ab [Units/volume] in Serum | 72 | [IU]/mL | <=29 [IU]/mL | High | S |
| 2026-07-27 | Complement C3 [Mass/volume] in Serum or Plasma | 84 | mg/dL | 90-180 mg/dL | Low | S |
| 2026-07-27 | Complement C4 [Mass/volume] in Serum or Plasma | 13 | mg/dL | 10-40 mg/dL | Normal | S |
| 2026-07-27 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 | ng/mL | 30-100 ng/mL | Normal | S |
| 2026-07-27 | Cholesterol [Mass/volume] in Serum or Plasma | 212 | mg/dL | <=199 mg/dL | High | S |
| 2026-07-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-07-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=99 mg/dL | High | S |
| 2026-07-27 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-07-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.3 | % | <=5.6% | Normal | S |
| 2026-07-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-07-27 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 | {score} | S |
Vital signs recorded on 2026-07-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; slight fullness of the face |
| Skin | No malar rash; no mouth ulcers |
| Musculoskeletal | No synovitis; full, painless hip movement |
| Cardiovascular | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be established | resolved | confirmed | M25.50 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D). |
| Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be established | resolved | confirmed | R80.9 | S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit. |
| Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negative | active | confirmed | M32.19 | S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used. |
| Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney function | active | confirmed | M32.14 | S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used. |
| Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or less | active | confirmed | Z79.52 | S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low. |
| Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in place | active | confirmed | Z79.624 | S — Synthetic treatment status. |
| Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatment | active | confirmed | Z97.5 | S — Synthetic contraception, chosen by the patient. |
| Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoin | resolved | confirmed | N30.00 | S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Urine protein-to-creatinine ratio and urine sediment | Every 3 months during active treatment | Completed today | 0.9 g/g, from 1.8; 6 red cells per high-power field |
| Laboratory | Creatinine, eGFR, and albumin | Every 3 months during active treatment | Completed today | Creatinine 0.8, eGFR 101, albumin 3.8 |
| Laboratory | Anti-dsDNA, C3, and C4 | Every 3 months during active treatment | Completed today | Anti-dsDNA 72; C3 84; C4 13 |
| Laboratory | Blood count and liver tests on mycophenolate | Weekly for a month, twice monthly for two months, then monthly | Completed today | White cells 5.2, lymphocytes 1.0, hemoglobin 12.1, platelets 212; ALT 22; earlier rheumatology counts normal |
| Laboratory | Potassium and creatinine after starting losartan | 2 to 4 weeks after starting | Deferred | Missed, a deviation from the protocol: the check due two to four weeks after losartan was started was not drawn, because the standing rheumatology orders were for blood counts only. The first potassium, at the sick visit seven and a half weeks after starting, was 4.6 with creatinine unchanged at 0.8, so no harm resulted. Corrective action: a basic metabolic panel was added to the standing orders at that visit, and any dose change will be followed by a check at two weeks |
| Laboratory | Potassium | With each kidney panel on losartan | Completed today | 4.4 mmol/L |
| Examination | Blood pressure | Every visit | Completed today | 122/78 mmHg, at target |
| Laboratory | Glucose and lipids on glucocorticoids | At three months | Completed today | HbA1c 5.3 percent; total cholesterol 212, HDL 58, LDL 128, triglycerides 130 |
| Laboratory | 25-hydroxyvitamin D | After repletion | Completed today | 36 ng/mL |
| Examination | Avascular necrosis symptoms | Every visit | Completed today | No hip, groin, or knee pain |
| Medication safety | Glucocorticoid dose | Every visit | Completed today | Prednisone 10 mg; on schedule for 5 mg or less by six months |
| Medication safety | Hydroxychloroquine baseline eye examination | Within the first year | Up to date | A month ago: fundus, OCT, and visual fields normal |
| Medication safety | Recombinant zoster vaccine dose 2 | 1 to 2 months after dose 1 | Completed today | Given today |
| Medication safety | Contraception on mycophenolate | Every visit | Up to date | Intrauterine system in place |
| Survey | Mood on belimumab (PHQ-9) | Periodically | Completed today | PHQ-9 4 |
| Survey | Joint pain score | Every visit | Completed today | 1 of 10 |
| Self-management | Sun protection and writing schedule | Every visit | Completed today | Sunscreen daily; writing five mornings a week |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]
Guideline basis: EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023); 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024); 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022); CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease and hypertension monographs (2026)
Follow-up: Prednisone to 7.5 mg next month. Rheumatology blood counts monthly. Preventive visit in October. Six-month review. Next scheduled visit 2026-10-05: adult preventive visit. [S]